Biohaven Pharmaceutical, a privately owned biopharmaceutical firm based in Newhaven, Connecticut, in the US, has appointed John Tilton as Chief Commercial Officer.
Tilton has joined the firm from Alexion Pharmaceuticals where he was an Executive Director. Previously, he held leadership roles at Pfizer, Agouron and Sanofi with therapeutic focus in the orphan, oncology and speciality markets.
In this newly created position, Tilton will lead Biohaven's commercialisation activities.
Biohaven is engaged in the identification and development of clinical stage compounds targeting the glutamatergic system and other neurological pathways. The firm has licensed intellectual property from Yale University, Catalent and Massachusetts General Hospital.
It is owned by a group of investors including Portage Biotech, Yale University and other private investors.
